Aditxt, Inc. (ADTX)
Automate Your Wheel Strategy on ADTX
With Tiblio's Option Bot, you can configure your own wheel strategy including ADTX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ADTX
- Rev/Share 0.0786
- Book/Share 22.4027
- PB 0.0577
- Debt/Equity 0.2366
- CurrentRatio 0.0804
- ROIC -1630.3259
- MktCap 2883268.0
- FreeCF/Share -31.9961
- PFCF -0.1281
- PE -0.0376
- Debt/Assets 0.1257
- DivYield 0
- ROE -2.7686
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 5
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Aditxt Announces Termination of Arrangement Agreement With Appili Therapeutics
Published: May 19, 2025 by: Business Wire
Sentiment: Neutral
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform accelerating promising health innovations, today announced that it has determined it is in the best interest of the Company and its stockholders to terminate the previously announced Arrangement Agreement with Appili Therapeutics, Inc. The Arrangement Agreement, originally announced in April 2024, had been amended several times to extend key milestones and accommodate ch.
Read More
Upcoming Aditxt Weekly Update to Feature Dr. Shahrokh Shabahang, Chief Innovation Officer (CIO) of Aditxt™, and Dr. Friedrich Kapp, Co-CEO of Adimune™, to Discuss Progress of Lead Therapeutic Candidate ADI-100™
Published: May 02, 2025 by: Business Wire
Sentiment: Neutral
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, announced that Aditxt's CIO Dr. Shahrokh Shabahang, and Adimune's Co-CEO Dr. Friedrich Kapp, will join today's Aditxt Weekly Update to discuss recent developments related to ADI-100™, the lead therapeutic candidate of its wholly owned subsidiary, Adimune. Event Details: Title: Aditxt Weekly Update Date: Friday, May 2, 2025 Time:.
Read More
Aditxt Subsidiary Pearsanta Engages Dominari Securities for its Initial Public Offering, to Drive U.S. and Global Commercial Launch of Early Cancer Detection and Diagnosis Targeted for H2 2025
Published: February 21, 2025 by: Business Wire
Sentiment: Neutral
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, today announced that its subsidiary, Pearsanta, Inc. (“Pearsanta”), has engaged Dominari Securities LLC as lead underwriter for Pearsanta's planned initial public offering (IPO). The proposed IPO, advised by Dominari Securities, is intended to support Pearsanta's U.S. and international commercial launch efforts and.
Read More
About Aditxt, Inc. (ADTX)
- IPO Date 2020-06-30
- Website https://www.aditxt.com
- Industry Biotechnology
- CEO Mr. Amro A. Albanna
- Employees 26